AAD
  • Meeting Program
  • Registration
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Topics
  • Daily Coverage
  • Photo Gallery
  • Samples & Solutions
Resources
  • Meeting Program
  • Registration
Facebook iconInstagram iconTwitter X icon
Mar 18, 2023

Dermatology’s history, role in treating STIs

Now, mpox joins the list.


Left to right: Kieron Leslie, MBBS, and Albert Liu, MD, MPH
Left to right: Kieron Leslie, MBBS, and Albert Liu, MD, MPH

Dermatologists are on the front lines in the ongoing battle to prevent and treat sexually transmitted infections.

“Dermatology as a specialty began from a study of syphilology because syphilis causes so many, many skin rashes,” said Kieron Leslie, MBBS, professor of dermatology at the University of California, San Francisco (UCSF) School of Medicine. “Similarly, condyloma, mpox, and many other sexually transmitted infections (STIs) are primarily diseases of the skin. When someone comes in with a lesion on the face, the hands, the trunk, they may not share that they also have genital lesions. You need to have an index of suspicion that this might be an STI.”

Thinking outside the pox

Dr. Leslie opened “F014 – HIV and STIs: Hot Topics” with an update on the latest skin disease to jump from animals to humans, mpox. Since the 1950s, mpox had been considered a zoonotic infection endemic to parts of Africa that can jump from animals to humans, but human-human transmission was rare. That changed in 2022 when mpox suddenly surged to pandemic status. Spread largely, but not exclusively, through sexual contact, mpox can present as a mild rash to more painful and severe rashes and anogenital lesions.

The good news, according to Dr. Leslie, is that incidence rates in the United States have fallen significantly since the summer of 2022. The drop is likely due to a combination of aggressive vaccination, emphasis on safe sex practices, and widespread infection among the most susceptible populations.

“Dermatologists need to be aware of the morphology of mpox and other STIs because cases continue to present,” Dr. Leslie said. “Symptom control is standard of care for mild disease with analgesia for more severe forms. For severe disease, antivirals potentially active against poxvirus are appropriate.”

Jump on STOMP

The primary antiviral is tecovirimat, approved under an Emergency Use Authorization (EUA). The agent is also being evaluated in STOMP, the Study of Tecovirimat for Human Mpox.

“For patients who present with mpox, we recommend they get enrolled in STOMP,” he said. “Tecovirimat has been evaluated in phase I safety trials and is effective in monkeys, but efficacy in humans has not been evaluated. We hope STOMP will answer the question. Mpox remains a long-standing infectious disease that presents in the skin. Dermatologists need to be aware of what the rashes and lesions look like and be able to refer to appropriate treatment.”

Making safe sex even safer

Practitioners need to be equally familiar with syphilis, HIV, condyloma, and other STIs and the latest prevention strategies. And although treatments are available, prevention is preferred.

Safe sex practices can make a significant difference, Dr. Leslie said. So can vaccination, which has dramatically reduced the incidence and prevalence of condyloma and other sequelae of human papilloma virus (HPV) infection. 

The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination for all individuals up to the age of 26 and up to age 45 based on individual factors. HPV vaccination is not recommended for older individuals based on both the likelihood of prior HPV infection and the generally lower immune response in older individuals.

PrEP, preexposure prophylaxis, has been used to prevent HIV transmission for a decade, as has PEP (post exposure prophylaxis), according to Albert Liu, MD, MPH, assistant clinical professor at the UCSF School of Medicine and director of HIV Prevention, San Francisco Department of Public Health. The same PrEP-PEP approach has been extended to syphilis using doxycycline, a perennial treatment of choice for acute and secondary syphilis. 

“Using doxy as PrEP and PEP is new for syphilis, but the strategies are well established and successful in HIV,” Dr. Liu said. “Dermatologists need to understand that there are highly effective prevention strategies for HIV and syphilis and be comfortable talking with patients about their sexual history and activity.”  

Interesting Stories
DermWorld May | Deciding the right time for treatment
Presented by AAD
DermWorld May | Deciding the right time for treatment
DermWorld February | Glow Up
Presented by AAD
DermWorld February | Glow Up
DermWorld April | Shedding light on treatments for female pattern hair loss
Presented by AAD
DermWorld April | Shedding light on treatments for female pattern hair loss
DermWorld March | Publishing profiteers
Presented by AAD
DermWorld March | Publishing profiteers
Dermworld June | Smoke and the skin
Presented by AAD
Dermworld June | Smoke and the skin
DermWorld  January | Scar solutions
Presented by AAD
DermWorld January | Scar solutions
More in AAD 2023 Annual Meeting
2022 03 21 12 26 25 6238b55bf2d38
AAD 2023 Annual Meeting
Claim CME
Claim CME
Feb 19, 2024
Phone in hand showing mobile app
2024 AAD Annual Meeting
Download the Annual Meeting app
Download the AAD Meeting app here
Feb 17, 2024
Session Director Raj Chovatiya, MD, PhD, FAAD
AAD 2023 Annual Meeting
When it looks and itches like atopic dermatitis. But isn’t.
Apr 07, 2023
Left to right: Kelly Tyler, MD, FAAD, and Howa Yeung, MD, FAAD
AAD 2023 Annual Meeting
Lifting the veil
Apr 07, 2023
Session director Trilokraj Tejasvi, MD, MBBS
AAD 2023 Annual Meeting
Decoding the benefits and burdens of technology in dermatology
Apr 07, 2023
Left to right: Rebecca I. Hartman, MD, MPH, FAAD, Abigail Baird Waldman, MD, FAAD, and Emily S. Ruiz, MD, FAAD.
AAD 2023 Annual Meeting
Surgery is not the only option for skin cancers
Apr 07, 2023
Terrence A. Cronin Jr., MD, FAAD
AAD 2023 Annual Meeting
From 17 to 20,000: New president accepts challenge of Academy’s 85-year growth
Apr 07, 2023
Left to right: Maria Aleshin, MD, FAAD, and Silvina Pugliese, MD, FAAD
AAD 2023 Annual Meeting
Beyond the familiar
Apr 07, 2023
Safi Bahcall
AAD 2023 Annual Meeting
Nurture the unexpected
Mar 20, 2023
Richard L. Gallo, MD, PhD, FAAD
AAD 2023 Annual Meeting
New approach uses microbiome to treat skin disease
Mar 20, 2023
Camp Discovery 92
AAD 2023 Annual Meeting
Refer a patient to Camp Discovery!
Mar 20, 2023
Amy J. McMichael, MD, FAAD
AAD 2023 Annual Meeting
A question of belonging
Mar 20, 2023
AAD
Facebook iconInstagram iconTwitter X icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.